Drugs / AZD7503
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06093542 | Oct 2023 → Mar 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05864391 | Mar 2023 → Mar 2024 | metabolic dysfunction-associated steatohepatitis | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT05560607 | Aug 2022 → Nov 2023 | NAFLD1, metabolic dysfunction-associated steatohepatitis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05143905 | Dec 2021 → Nov 2022 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7503 | “Randomised participants will receive AZD7503 subcutaneously.” NCT06093542 ↗ |
| Route | Subcutaneous | “following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.” NCT05143905 ↗ |